To view this release in French click here
QUMAS, an Accelrys company (NASDAQ: ACCL), today announced that Pierre Fabre Laboratories, a leading pharmaceutical and cosmetics company with headquarters in Castres, France, has selected QUMAS DocCompliance to manage and control quality documents across the entire company. The QUMAS Compliance Platform was selected after an extensive evaluation process conducted by members of the Quality Assurance and IT teams at Pierre Fabre Laboratories. The QUMAS solution will be rolled out to 3,850 Pierre Fabre employees initially.
QUMAS DocCompliance provides Pierre Fabre Laboratories with a complete web-based electronic document management system that enables users to create, manage, circulate and securely store all documents and content related to quality assurance and quality control across the company’s product portfolio. The platform fully supports Electronic Signatures as per the FDA 21 CFR Part 11 requirements and is configurable, allowing companies to mirror their organizational structures and practices. All of the compliance capabilities of the platform are accessed through MyQUMAS, a user-friendly web-based interface.
“QUMAS provides Pierre Fabre with a scalable solution that will enable employees across all of its product sites to collaborate on quality assurance content and documents in a controlled, compliant and fully auditable manner,” stated Kevin O’Leary, CEO for QUMAS. “We are delighted to be adding another leading French company to our client list, and plan to increase our client base in Europe significantly this year.”
“We conducted a very thorough evaluation of a number of vendor solutions,” commented Pierre Contreras, business project director for Pierre Fabre Laboratories. “We were very impressed with the advanced features of DocCompliance and its large reference base of companies across our industry, as well as the professionalism and responsiveness of the QUMAS team.”
QUMAS is the leader in Enterprise Compliance Solutions with more than 270 global customer deployments and two decades of experience helping companies in highly regulated industries. QUMAS is a Gold Microsoft Partner, and provides the QUMAS Compliance Platform on SharePoint 2010, Documentum, Oracle or SQL. For more information, visit www.qumas.com.
QUMAS is an Accelrys company. Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, QA/QC and manufacturing phases of product development. Accelrys offers capabilities in scientific data management, modeling and simulation, research informatics, laboratory informatics, enterprise quality management, environmental health & safety and operations intelligence for customers in science-driven industries. Using Accelrys technology, scientific innovators can access, organize, analyze and share data in unprecedented ways across the research, laboratory and manufacturing continuum, ultimately enhancing innovation, improving productivity and compliance, reducing costs and accelerating product development from research to manufacturing.
Accelrys solutions are used by more than 2,000 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs approximately 225 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.
About Pierre Fabre Laboratories
Pierre Fabre is the 3rd largest French pharmaceutical group. In 2013, its sales reached €2.008 Billion, with international revenues accounting for 56%. Founded and still based in the South-west of France, Pierre Fabre currently has branches in 44 countries and distribution agreements in over 130 countries.
Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide. Every year, the group allocates more than 17% of its drug revenues to R&D, focusing on three main areas: oncology, dermatology and neuropsychiatry.
With brands such as Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Naturactive, Elgydium, Eludril or Drill, Pierre Fabre Laboratories are market leaders when it comes to skin, hair and oral care products sold in French pharmacy channels. Avène is marketed worldwide, and is the leading dermo-cosmetics brand in Europe, Japan and China. In oncology, Pierre Fabre achieves 90% of its revenues outside of its home country.
Through the Pierre Fabre Participations holding company, the Pierre Fabre Foundation, a government-recognized public-interest foundation, owns 86% of Pierre Fabre Laboratories. 7% of remaining shares are owned by company employees, and 7% are treasury stock.
The French certification group AFNOR has audited Pierre Fabre Laboratories for its corporate social responsibility (CSR) performance at advanced level (AFAQ 26 000)
To find out more, please visit www.pierre-fabre.com.